Ariana expands operations to USA
Ariana Pharma announced that it has expanded its global operations by establishing a permanent US office in Cambridge, Massachusetts to service growing demand for its unique and powerful data analytics technology KEM (R).
In conjunction with the opening, Ariana has appointed James M. Shanahan as VP of business development. James was previously a co-founder and is current board member of SynDevRx, Inc., an oncology-focused biotech company and was a co-founder and VP corporate development of JAM Technologies, Inc. James brings 15 years business development and marketing experience to Ariana.
“The US pharma and biotech markets tend to be early technology adopters, and are searching for better data analytics tools to advance personalized medicine using all the new biomarker, genomic, proteomic and metabolomic data now being generated,” said Dr. Mohammad Afshar, president and CEO of Ariana Pharma. “Our KEM technology is the only proven approach that can simultaneously analyze all these variables and pull out patient responder sub-groups, optimize biomarker signatures and remove bias from clinical trials.”
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
